Close Menu

More articles about Reproductive Health

A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.  

 

The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.

The company said three clinical centers have validated the test in a prospective clinical trial involving more than 10,000 participants.

The Unity test enables screening for several autosomal recessive conditions from fetal DNA gathered from maternal blood.

The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.

The nonpartisan federal agency's report suggests ways for Congress, the FDA, FTC, and CMS to expand oversight of the genetic testing market.

The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.

The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.

Next week at the American Society of Human Genetics annual meeting, LabCorp researchers plan to present results from almost 1,000 triplet pregnancies.

Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.

PWNHealth will provide physician oversight and genetic counseling for Picture Genetics, a new line of three genetic tests from Fulgent aimed at consumers.

The company published a quality assurance study for the Panorama test last month and is wrapping up the SMART study, which has enrolled 20,000 women.

The test is the first near-patient assay for M. genitalium, and can also guide treatment by detecting antibacterial resistance markers.

New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.

The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.

The clearance of the Binx io CT/NG test marks a milestone for the Johns Hopkins University group that funds early-stage development of rapid STI testing.

Illumina plans to upgrade all its NIPT customers to version 2 of its VeriSeq solution over the next year.

The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.

The Cyprus-based company has been offering a cell-free DNA-based noninvasive prenatal test for fetal aneuploidies, called Veracity, since 2015.

During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.

Pages